LLY

1,062.66

+1.87%↑

JNJ

205.45

+0.96%↑

ABBV

237.09

+3.18%↑

UNH

319.81

+2.36%↑

AZN

91.59

+3.15%↑

LLY

1,062.66

+1.87%↑

JNJ

205.45

+0.96%↑

ABBV

237.09

+3.18%↑

UNH

319.81

+2.36%↑

AZN

91.59

+3.15%↑

LLY

1,062.66

+1.87%↑

JNJ

205.45

+0.96%↑

ABBV

237.09

+3.18%↑

UNH

319.81

+2.36%↑

AZN

91.59

+3.15%↑

LLY

1,062.66

+1.87%↑

JNJ

205.45

+0.96%↑

ABBV

237.09

+3.18%↑

UNH

319.81

+2.36%↑

AZN

91.59

+3.15%↑

LLY

1,062.66

+1.87%↑

JNJ

205.45

+0.96%↑

ABBV

237.09

+3.18%↑

UNH

319.81

+2.36%↑

AZN

91.59

+3.15%↑

Search

Revvity Inc

Open

BrancheGesundheitswesen

98.54 5.76

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

93.57

Max

98.86

Schlüsselkennzahlen

By Trading Economics

Einkommen

-8.6M

47M

Verkäufe

-21M

699M

KGV

Branchendurchschnitt

46.938

106.172

EPS

1.18

Dividendenrendite

0.3

Gewinnspanne

6.675

Angestellte

11,000

EBITDA

-14M

181M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+20.43% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.30%

2.31%

Nächstes Ex-Dividendendatum

16. Jan. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-708M

11B

Vorheriger Eröffnungskurs

92.78

Vorheriger Schlusskurs

98.54

Nachrichtenstimmung

By Acuity

23%

77%

37 / 374 Ranking in Healthcare

Revvity Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Nov. 2025, 23:07 UTC

Market Talk

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

20. Nov. 2025, 22:22 UTC

Market Talk

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

20. Nov. 2025, 22:08 UTC

Market Talk

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

20. Nov. 2025, 21:57 UTC

Ergebnisse

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

20. Nov. 2025, 21:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

20. Nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20. Nov. 2025, 21:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

20. Nov. 2025, 21:50 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

20. Nov. 2025, 21:31 UTC

Ergebnisse

Nvidia's Strong Results Show AI Fears Are Premature -- Update

20. Nov. 2025, 21:23 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20. Nov. 2025, 21:07 UTC

Ergebnisse

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20. Nov. 2025, 21:06 UTC

Ergebnisse

Webull 3Q Rev $156.9M >BULL

20. Nov. 2025, 21:06 UTC

Ergebnisse

Webull 3Q EPS 7c >BULL

20. Nov. 2025, 21:05 UTC

Ergebnisse

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

20. Nov. 2025, 21:04 UTC

Ergebnisse

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

20. Nov. 2025, 21:04 UTC

Ergebnisse

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

20. Nov. 2025, 21:04 UTC

Ergebnisse

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20. Nov. 2025, 21:00 UTC

Ergebnisse

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

20. Nov. 2025, 21:00 UTC

Ergebnisse

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

20. Nov. 2025, 21:00 UTC

Ergebnisse

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

20. Nov. 2025, 21:00 UTC

Ergebnisse

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

20. Nov. 2025, 21:00 UTC

Ergebnisse

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

20. Nov. 2025, 21:00 UTC

Ergebnisse

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

20. Nov. 2025, 21:00 UTC

Ergebnisse

Intuit Backs FY26 Rev $21B-$21.19B >INTU

20. Nov. 2025, 21:00 UTC

Ergebnisse

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

20. Nov. 2025, 21:00 UTC

Ergebnisse

Intuit 1Q Consumer Rev $894M

20. Nov. 2025, 21:00 UTC

Ergebnisse

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

20. Nov. 2025, 21:00 UTC

Ergebnisse

Intuit Backs FY26 Guidance

20. Nov. 2025, 21:00 UTC

Ergebnisse

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

20. Nov. 2025, 21:00 UTC

Ergebnisse

Intuit 1Q Global Business Solutions Rev $3B

Peer-Vergleich

Kursveränderung

Revvity Inc Prognose

Kursziel

By TipRanks

20.43% Vorteil

12-Monats-Prognose

Durchschnitt 111.1 USD  20.43%

Hoch 125 USD

Tief 100 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Revvity Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

8

Buy

3

Halten

0

Sell

Stimmung

By Acuity

37 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat